Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

Alcoholic cirrhosis isn’t something that appears overnight. It is the tragic result of long-term alcohol use that scars and weakens the liver, stopping it from doing vital tasks.

Cirrhosis or fibrosis of the liver can occur due to several liver-related diseases and conditions, such as hepatitis, non-alcoholic fatty liver disease, and excessive alcohol consumption.

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...